J Rheum Dis 2017; 24(1): 27-34
Published online February 28, 2017
© Korean College of Rheumatology
Correspondence to : Min-Chan Park, Division of Rheumatology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 06273, Korea. E-mail:mcpark@yuhs.ac
This is a Open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. This study was performed to assess the cost-effectiveness of cyclooxygenase-2 (COX2)-selective inhibitor, non-selective non-steroidal anti-inflammatory drugs (NSAIDs), and non-selective NSAID with proton pump inhibitors (PPIs) while considering upper and lower gastrointestinal (GI) safety in patients with rheumatoid arthritis (RA). Methods. A Markov model was used to estimate the costs and effectiveness. Estimates of therapeutic efficacy and upper/lower GI safety were based on results from large randomized controlled trials. The main outcome measure was cost effectiveness, based on the quality-adjusted life years (QALYs) gained. Safety parameters included clinical upper GI symptoms, uncomplicated ulcer, upper GI bleeding, upper GI perforation, clinical lower GI symptoms, lower GI bleeding, and lower GI perforation. Cost data were obtained from patients treated in a tertiary referral center in Korea. Results. The expected three year cost was 3,052,800 Korean won (KRW) for COX2-selective inhibitor, 3,170,800 KRW for nonselective NSAID, and 3,325,900 KRW for non-selective NSAID with PPI. QALYs were 2.87446, 2.85320, and 2.85815, respectively. The total cost for COX2-selective inhibitor use was lower than non-selective NSAID, but QALY was higher, indicating that the incremental cost effectiveness ratio of COX2-selective inhibitor is superior. Conclusion. COX2-selective inhibitor has reasonable cost-effectiveness adjusted for upper and lower GI toxicity for patients with RA in Korea.
Keywords Cost-effectiveness, Cox-2 selective inhibitor, Gastrointestinal toxicity, Non-steroidal anti-inflammatory drugs, Rheumatoid arthritis
J Rheum Dis 2017; 24(1): 27-34
Published online February 28, 2017 https://doi.org/10.4078/jrd.2017.24.1.27
Copyright © Korean College of Rheumatology.
Soo-Jin Chung1, Hye-Jin Park2, Min-Chan Park1
1Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 2School of Pharmacy,Sungkyunkwan University, Suwon, Korea
Correspondence to:Min-Chan Park, Division of Rheumatology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 06273, Korea. E-mail:mcpark@yuhs.ac
This is a Open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. This study was performed to assess the cost-effectiveness of cyclooxygenase-2 (COX2)-selective inhibitor, non-selective non-steroidal anti-inflammatory drugs (NSAIDs), and non-selective NSAID with proton pump inhibitors (PPIs) while considering upper and lower gastrointestinal (GI) safety in patients with rheumatoid arthritis (RA). Methods. A Markov model was used to estimate the costs and effectiveness. Estimates of therapeutic efficacy and upper/lower GI safety were based on results from large randomized controlled trials. The main outcome measure was cost effectiveness, based on the quality-adjusted life years (QALYs) gained. Safety parameters included clinical upper GI symptoms, uncomplicated ulcer, upper GI bleeding, upper GI perforation, clinical lower GI symptoms, lower GI bleeding, and lower GI perforation. Cost data were obtained from patients treated in a tertiary referral center in Korea. Results. The expected three year cost was 3,052,800 Korean won (KRW) for COX2-selective inhibitor, 3,170,800 KRW for nonselective NSAID, and 3,325,900 KRW for non-selective NSAID with PPI. QALYs were 2.87446, 2.85320, and 2.85815, respectively. The total cost for COX2-selective inhibitor use was lower than non-selective NSAID, but QALY was higher, indicating that the incremental cost effectiveness ratio of COX2-selective inhibitor is superior. Conclusion. COX2-selective inhibitor has reasonable cost-effectiveness adjusted for upper and lower GI toxicity for patients with RA in Korea.
Keywords: Cost-effectiveness, Cox-2 selective inhibitor, Gastrointestinal toxicity, Non-steroidal anti-inflammatory drugs, Rheumatoid arthritis
Byeongzu Ghang, M.D., Ph.D., Jin Kyun Park, M.D., Ph.D., Ji Hyeon Ju, M.D., Ph.D., Seungwoo Han, M.D., Ph.D.
J Rheum Dis -0001; ():Shohei Anno, M.D., Kentaro Inui, M.D., Ph.D., Masahiro Tada, M.D., Ph.D., Yuko Sugioka, M.D., Ph.D., Tadashi Okano, M.D., Ph.D.,, Kenji Mamoto, M.D., Ph.D., Tatsuya Koike, M.D., Ph.D.
J Rheum Dis -0001; ():Soo Min Ahn, M.D., Ph.D., Seonok Kim, MSc., Ye-Jee Kim, Ph.D., Seokchan Hong, M.D., Ph.D., Chang-Keun Lee, M.D., Ph.D., Bin Yoo, M.D., Ph.D., Ji Seon Oh, M.D., Ph.D., Yong-Gil Kim, M.D., Ph.D.
J Rheum Dis -0001; ():